Aligos Therapeutics Presents Data on Chronic Hepatitis B, NASH and Hepatocellular Carcinoma Programs at AASLD's The Liver Meeting Digital Experience™ 2020
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has delivered six poster presentations and an oral presentation at this year’s American Association for the Study of Liver Diseases (AASLD) Liver Meeting Digital Experience™ (TLMdX) 2020, held virtually on November 13-16, 2020. The data presented includes updates from three of Aligos’ assets in its lead chronic hepatitis B (CHB) combination therapy platform, as well as data from the company’s nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC) programs.
“We are proud of the progress we have made for the Aligos’ liver disease programs as outlined in our presentations during this year’s AASLD Liver Meeting,” said Lawrence Blatt, Ph.D., MBA, Chief Executive Officer of Aligos. “We are working towards producing a combination regimen of promising therapeutics that have the potential to lead to functional cures for patients living with chronic hepatitis B. Additionally, our team has made substantial progress on ALG-055009, a potent and selective purpose built THR beta agonist for the treatment of NASH. Two of our drug candidates, ALG-010133 (STOPS™) and ALG-000184 (CAM), aimed at the treatment of chronic hepatitis B have already begun Phase 1 clinical trials and we look forward to advancing the remainder of our liver disease portfolio towards clinical development over the coming year.”
Chronic hepatitis B
Antisense oligonucleotide (ASO)
Capsid assembly modulator (CAM)
S-antigen Transport-inhibiting Oligonucleotide Polymer (STOPS™)
Title: The S-Antigen Transport-Inhibiting Oligonucleotide Polymer (STOPS™) ALG-010133 Demonstrates a Favorable Preclinical Profile for the Treatment of Chronic Hepatitis B
Title: ALG-055009, a Potent and Selective THR Beta Agonist for the Treatment of NASH, Demonstrates Significant Cholesterol Reduction in a Diet-Induced Obese (DIO) Mouse Efficacy Model
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
Forward Looking Statements